Kalle Aaltonen - Concepedia

Author

Kalle Aaltonen

Also Known As

Bjorn Gudbjornsson, K Aaltonen, K. Aaltonen, K. J. Aaltonen, K.J. Aaltonen, Kalle Aaltonen, Kalle J Aaltonen, Kalle J. Aaltonen, Kalle Jyri Aaltonen

Publications

986

Citations

H-Index

Concepts

All Affiliations

Helsinki University Hospital University of Helsinki Tampere University Hospital Central Finland Health Care District Diakonhjemmet Hospital

About

Kalle Aaltonen is an author at Helsinki University Hospital specializing in medicine, rheumatology, and rheumatoid arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	152
2	Health Sciences	1	1	51
3	Public Health	1	1	10
4	Child Development	1	1	51
5	Epidemiology	1	1	10

Kalle Aaltonen

Publications

530

Citations

H-Index

Page 1

	Year	Citations
Rates of Serious Infections and Malignancies Among Patients with Rheumatoid Arthritis Receiving Either Tumor Necrosis Factor Inhibitor or Rituximab Therapy Kalle Aaltonen, J. Joensuu, Liisa Virkki, The Journal of Rheumatology	2015	78
Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study Arto Heinonen, Kalle Aaltonen, J. Joensuu, The Journal of Rheumatology	2015	55
Migraine Attacks and Sleep in Children Kalle Aaltonen, ML Hämäläinen, Kalle Hoppu Cephalalgia Sleep DisordersSleepSleep MedicineSleep DisorderHealth Sciences	2000	51
Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study Kalle Aaltonen, Arto Heinonen, Jaana Joensuu, Seminars in Arthritis and Rheumatism Rheumatoid DisorderRheumatologyMedicineDrug SurvivalOsteoarthritis	2016	48
Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study Kalle Aaltonen, Liisa Virkki, Esa Jämsen, Seminars in Arthritis and Rheumatism Rheumatoid DisorderRheumatologyBiologic DrugsRheumatic DiseasesRegister-based Study	2013	43
Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice Kalle Aaltonen, Suvi Ylikylä, Jaana Joensuu, Lara D. Veeken	2016	40
The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers Lianne Kearsley‐Fleet, Jakub Závada, Merete Lund Hetland, Lara D. Veeken	2014	31
Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study J. Joensuu, Kalle Aaltonen, Pasi Aronen, Lara D. Veeken	2016	27
<scp>One‐Year</scp> Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses Bente Glintborg, Ulf Lindström, Daniela Di Giuseppe, Arthritis Care & Research	2020	26
Biological treatment in ankylosing spondylitis in the Nordic countries during 2010–2016: a collaboration between five biological registries Bente Glintborg, Ulf Lindström, Kalle Aaltonen, Scandinavian Journal of Rheumatology	2018	25

Page 1